The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1/2 study of zilovertamab and ibrutinib in mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL).
 
Hun Ju Lee
Honoraria - Aptitude Health; Cancer Experts Now; Century Therapeutics; Curio Science
Consulting or Advisory Role - BMS; Guidepoint Global
Research Funding - BMS; Celgene; Celgene; Oncternal Therapeutics; Seagen; Takeda
 
Michael Y. Choi
Research Funding - Oncternal Therapeutics (Inst); Pharmacyclics (Inst); Sunesis Pharmaceuticals (Inst); TG Therapeutics (Inst); VelosBio (Inst)
 
Tanya Siddiqi
Consulting or Advisory Role - AstraZeneca; BeiGene; Bristol-Myers Squibb/Celgene; Celgene; Juno Therapeutics; Pharmacyclics
Speakers' Bureau - AstraZeneca; BeiGene; Bristol-Myers Squibb/Celgene; Pharmacyclics/Janssen
Research Funding - Acerta Pharma (Inst); BeiGene (Inst); Bristol-Myers Squibb/Sanofi (Inst); Celgene (Inst); Juno Therapeutics (Inst); Kite, a Gilead company (Inst); Oncternal Therapeutics (Inst); Pharmacyclics (Inst); TG Therapeutics (Inst)
 
Joanna Meehan Rhodes
Honoraria - Curio Science; Dava Oncology
Consulting or Advisory Role - Abbvie; BeiGene; Genentech; Janssen; Morphosys; Pharmacyclics; Seagen; TG Therapeutics; Verastem
Research Funding - Loxo/Lilly (Inst)
Travel, Accommodations, Expenses - Curio Science; DAVA Pharmaceuticals; Loxo
 
William G. Wierda
Consulting or Advisory Role - Sanofi
Research Funding - Abbvie; Acerta Pharma; Cyclacel; Genentech; Gilead Sciences; GlaxoSmithKline/Novartis; Janssen; Juno Therapeutics; Kite, a Gilead company; Loxo; miRagen; Oncternal Therapeutics, Inc; Pharmacyclics; Sunesis Pharmaceuticals; Xencor
 
Iris Isufi
Consulting or Advisory Role - ADC Therapeutics; Beam Therapeutics; Celgene/Jazz; Epizyme; Kite, a Gilead company
Speakers' Bureau - Kite, a Gilead company
 
Joseph M. Tuscano
Research Funding - Celgene; Genentech; Novartis; Pharmacyclics; Seagen; Spectrum Pharmaceuticals
 
Nicole Lamanna
Consulting or Advisory Role - Abbvie; AstraZeneca; BeiGene; BeiGene; Celgene; Genentech; Gilead Sciences; Janssen; Juno Therapeutics; Loxo/Lilly; pharmacyclics; ProNAi; Roche
Research Funding - Abbvie (Inst); Acerta Pharma/AstraZeneca (Inst); AstraZeneca (Inst); Beigene (Inst); Genentech/Abbvie (Inst); Gilead Sciences (Inst); Infinity Pharmaceuticals (Inst); Juno Therapeutics (Inst); Loxo (Inst); MingSight (Inst); Octapharm (Inst); Oncternal Therapeutics, Inc (Inst); ProNAi (Inst); TG Therapeutics (Inst); Verastem (Inst)
 
Suki Subbiah
No Relationships to Disclose
 
Jean Louise Koff
Consulting or Advisory Role - Gamida Cell; Janssen/Pharmacyclics; MorphoSys; TG Therapeutics
Research Funding - Atara Biotherapeutics; Celgene; Janssen/Pharmacyclics; Oncternal Therapeutics; Viracta Therapeutics
 
Lori Ann Leslie
Consulting or Advisory Role - Abbvie; AstraZeneca/Merck; BeiGene; Celgene/Bristol-Myers Squibb; Epizyme; Janssen/Pharmacyclics; Kite/Gilead; Merck; Seagen; TG Therapeutics
Speakers' Bureau - AstraZeneca; BeiGene; Celgene; Epizyme; Janssen; Karyopharm Therapeutics; Kite, a Gilead company; Pharmacyclics; Seagen; TG Therapeutics
 
Alec Goldenberg
No Relationships to Disclose
 
Gina G. Chung
No Relationships to Disclose
 
Salim Yazji
Employment - Oncternal Therapeutics, Inc
Leadership - Oncternal Therapeutics, Inc
Stock and Other Ownership Interests - Oncternal Therapeutics, Inc
 
Yao Wang
Employment - Oncternal Therapeutics, Inc
Stock and Other Ownership Interests - Abbvie; Amgen; Intra-Cellular Therapies; Oncternal Therapeutics, Inc
 
James Bradley Breitmeyer
Employment - Oncternal Therapeutics, Inc
Leadership - Oncternal Therapeutics, Inc; Otonomy; Zogenix
Stock and Other Ownership Interests - Oncternal Therapeutics, Inc; Oncternal Therapeutics, Inc (I); Otonomy; Zogenix
Patents, Royalties, Other Intellectual Property - Inventor on patent(s)
Travel, Accommodations, Expenses - Oncternal Therapeutics, Inc; Zogenix
 
Michael Wang
Honoraria - Acerta Pharma; AstraZeneca; BeiGene; Breast-Gynecological International Cancer Society; CAHON; Chinese Anti-Cancer Association; Chinese Medical Association; Clinical Care Options; Dava Oncology; Epizyme; Hebei Cancer Prevention Federation; Imedex; Janssen Research & Development; Kite, a Gilead company; Miltenyi Biomedicine; Moffit Cancer Center; Mumbai Hematology Group; Newbridge Pharmaceuticals; OM Pharmaceutical Industries; Pharmacyclics/Janssen; Physicans' Education Resource; Scripps Health; The First Affiliated Hospital of Zhejiang University
Consulting or Advisory Role - AstraZeneca; Bayer; BeiGene; Bioinvent; CStone Pharmaceuticals; DTRM; Epizyme; Genentech; Guidepoint Global; Innocare; Janssen Research & Development; Juno Therapeutics; Kite, a Gilead company; Loxo; Miltenyi Biomedicine; Oncternal Therapeutics; Pharmacyclics/Janssen; Pulse Biosciences; VelosBio
Research Funding - Acerta Pharma; AstraZeneca; BeiGene; Bioinvent; Celgene; Innocare; Janssen Research & Development; Juno Therapeutics; Kite, a Gilead company; Lilly; Loxo; Molecular Templates; Oncternal Therapeutics; Pharmacyclics; VelosBio
Travel, Accommodations, Expenses - AstraZeneca; Celgene; Dava Oncology; Janssen Research & Development; OM Pharmaceutical Industries
 
Catriona Jamieson
Stock and Other Ownership Interests - ASPEN Group
Patents, Royalties, Other Intellectual Property - Patent Royalties- Methods for Manipulating Phagocytosis Mediated by CD47, Patent #US20090191202A1
 
Thomas J. Kipps
Employment - Moores Cancer Center
Stock and Other Ownership Interests - Oncternal Therapeutics, Inc
Honoraria - Abbvie; AstraZeneca; Dava Oncology; Genentech; Gilead Sciences; Janssen; Pharmacyclics
Consulting or Advisory Role - Abbvie; Dava Oncology; Genentech; Janssen; Pharmacyclics
Speakers' Bureau - Abbvie/Genentech; DAVA Pharmaceuticals; Gilead Sciences; Pharmacyclics/Janssen; Verastem/Pharmacyclics
Research Funding - Breast Cancer Research Foundation (Inst); California Institute for Regenerative Medicine (CIRM) (Inst); Leukemia and Lymphoma Society (Inst); National Cancer Institute (Inst); NIH (Inst); Oncternal Therapeutics, Inc (Inst); Pharmacyclics/Janssen (Inst)
Patents, Royalties, Other Intellectual Property - Cirmtuzumab was developed by Thomas J. Kipps in the Thomas J. Kipps laboratory and licensed by the University of California to Oncternal Therapeutics, Inc., which provided stock options and research funding to the Thomas J. Kipps laboratory. (Inst)
Travel, Accommodations, Expenses - Abbvie/Pharmacyclics; AstraZeneca; Breast Cancer Research Foundation; Celgene; Dava Oncology; Genentech/Roche; Gilead Sciences; Janssen; TG Therapeutics; Verastem